{"id":"retigabine","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT01457989","NCT01721213","NCT01938560","NCT01721317","NCT00310375","NCT03043560","NCT01823159","NCT01668654","NCT02450552","NCT01332513","NCT01336621","NCT01214278","NCT01227902","NCT01462656","NCT00235755","NCT04639310","NCT06941168","NCT02727101","NCT01462669","NCT00310388","NCT01583036","NCT01648101","NCT01587339","NCT01777139","NCT00232596","NCT01480609","NCT02149836","NCT04912856","NCT01607346","NCT00612105","NCT01691872","NCT01494584"],"aliases":["GKE-841","D-23129","ezogabine"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Retigabine","companyId":"bausch-health-americas-inc","ecosystem":[],"mechanism":{"target":"Potassium voltage-gated channel subfamily KQT member 2, Potassium voltage-gated channel subfamily KQT member 3, Potassium voltage-gated channel subfamily KQT member 4","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Bausch Health Americas, Inc.","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Retigabine","indications":{"approved":[{"name":"Partial Epilepsy Treatment Adjunct","diseaseId":"partial-epilepsy-treatment-adjunct","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01457989","phase":"N/A","title":"Meta-Analysis of VRX-RET-E22-303 and VRX-RET-E22-304: Two Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Studies of Retigabine in Adult Epilepsy Patients With Partial-onset Seiz","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":1,"indication":"Epilepsy, Partial","completionDate":"2011-08"},{"nctId":"NCT01721213","phase":"N/A","title":"European Survey of Patient and Prescriber Understanding of Risks Associated With Trobalt™","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":1,"indication":"Epilepsy","completionDate":"2013-12"},{"nctId":"NCT01938560","phase":"N/A","title":"REMS Prescriber and Pharmacist Understanding of the Risk of Urinary Retention With POTIGA™","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":1,"indication":"Epilepsy","completionDate":"2013-05"},{"nctId":"NCT01721317","phase":"Phase 4","title":"Study PTG116878, a Dose-Optimization Study of Ezogabine/Retigabine Immediate Release Tablets Versus Placebo in the Adjunctive Treatment of Subjects With Partial-Onset Seizures","status":"TERMINATED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":6,"indication":"Seizures","completionDate":"2013-06-20"},{"nctId":"NCT00310375","phase":"Phase 3","title":"A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":181,"indication":"Epilepsy","completionDate":"2017-03-15"},{"nctId":"NCT03043560","phase":"Phase 2","title":"Developing Neuronal KCNQ Channel Modulators for Mood Disorders","status":"COMPLETED","sponsor":"James Murrough","isPivotal":false,"enrollment":45,"indication":"Depressive Disorder, Anhedonia","completionDate":"2019-08-30"},{"nctId":"NCT01823159","phase":"Phase 3","title":"Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study","status":"COMPLETED","sponsor":"University Hospital of Mont-Godinne","isPivotal":true,"enrollment":15,"indication":"Epilepsy","completionDate":"2014-01"},{"nctId":"NCT01668654","phase":"Phase 3","title":"RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects With Partial Onset Seizures (>= 12 Years Old) and Subjects With Lennox-Gastaut Syndrome (>=12 Ye","status":"TERMINATED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":4,"indication":"Epilepsy","completionDate":"2013-06-18"},{"nctId":"NCT02450552","phase":"Phase 2","title":"A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Brian Wainger","isPivotal":false,"enrollment":65,"indication":"Amyotrophic Lateral Sclerosis","completionDate":"2018-02"},{"nctId":"NCT01332513","phase":"Phase 1","title":"An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":36,"indication":"Epilepsy","completionDate":"2011-05-23"},{"nctId":"NCT01336621","phase":"Phase 3","title":"A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults With Partial-Onset Seizures (Extension of Study RGB113905)","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":98,"indication":"Epilepsy","completionDate":"2017-09-13"},{"nctId":"NCT01214278","phase":"Phase 4","title":"Relative Bioavailability of Different n-3 Fatty Acid Formulations in Humans","status":"COMPLETED","sponsor":"Gottfried Wilhelm Leibniz Universität Hannover","isPivotal":false,"enrollment":12,"indication":"Health","completionDate":"2011-07"},{"nctId":"NCT01227902","phase":"Phase 3","title":"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":203,"indication":"Epilepsy","completionDate":"2012-12"},{"nctId":"NCT01462656","phase":"N/A","title":"A Post Marketing Surveillance Study to Monitor the Risk of Urinary Retention in Retigabine Users","status":"TERMINATED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":1,"indication":"Epilepsy","completionDate":"2016-08"},{"nctId":"NCT00235755","phase":"Phase 3","title":"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therap","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":539,"indication":"Seizures","completionDate":"2008-04"},{"nctId":"NCT04639310","phase":"Phase 3","title":"A Phase 3 Study of Adjunctive XEN496 in Pediatric Subjects With KCNQ2 Developmental and Epileptic Encephalopathy","status":"TERMINATED","sponsor":"Xenon Pharmaceuticals Inc.","isPivotal":true,"enrollment":8,"indication":"Epilepsy, Epilepsy in Children","completionDate":"2023-05-16"},{"nctId":"NCT06941168","phase":"N/A","title":"Potential Advantages of Robotic Total Gastrectomy in Advanced Middle-Upper Gastric Cancer","status":"COMPLETED","sponsor":"Fujian Medical University","isPivotal":false,"enrollment":1099,"indication":"Advanced Gastric Cancer","completionDate":"2024-08"},{"nctId":"NCT02727101","phase":"Phase 4","title":"\"Rational Polytherapy\" Using Perampanel Dual Therapy Anticonvulsant Combination Treatments of Adults With Refractory Focal Epilepsy : a Pilot Study.","status":"TERMINATED","sponsor":"Mid-Atlantic Epilepsy and Sleep Center, LLC","isPivotal":false,"enrollment":8,"indication":"Epilepsy","completionDate":"2017-07"},{"nctId":"NCT01462669","phase":"Phase 1","title":"An Open-label, Randomized, Single Centre, 4-way Crossover Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ezogabine/Retigabine in Healthy Adult Taiwanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":1,"indication":"Epilepsy","completionDate":"2012-06-27"},{"nctId":"NCT00310388","phase":"Phase 3","title":"A Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-Onset Seizures (Extension of Study VRX-RET-E22-302)","status":"TERMINATED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":376,"indication":"Epilepsy","completionDate":"2018-05-24"},{"nctId":"NCT01583036","phase":"Phase 1","title":"An Interaction Study to Assess the Effect of the Ezogabine/Retigabine and the Main Metabolite NAMR on the Pharmacokinetics of Digoxin in Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":30,"indication":"Epilepsy","completionDate":"2012-04-17"},{"nctId":"NCT01648101","phase":"Phase 3","title":"A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Determine the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Ad","status":"TERMINATED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":76,"indication":"Epilepsy","completionDate":"2013-12-23"},{"nctId":"NCT01587339","phase":"N/A","title":"Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":6498,"indication":"Epilepsy","completionDate":"2011-07"},{"nctId":"NCT01777139","phase":"Phase 3","title":"A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (Extension of Study RTG114855)","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":30,"indication":"Epilepsy","completionDate":"2017-09-13"},{"nctId":"NCT00232596","phase":"Phase 3","title":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epil","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":306,"indication":"Seizures","completionDate":"2008-01"},{"nctId":"NCT01480609","phase":"Phase 1","title":"An Open Label, Single-dose, Fixed Sequence, Two Treatment Period Study to Assess the Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Re","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":8,"indication":"Epilepsy","completionDate":"2012-04-24"},{"nctId":"NCT02149836","phase":"Phase 2","title":"A Proof-Of-Concept Clinical Trial of a Novel KCNQ Potentiator in Major Depressive Disorder","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","isPivotal":false,"enrollment":18,"indication":"Major Depressive Disorder, Depression","completionDate":"2016-12"},{"nctId":"NCT04912856","phase":"Phase 3","title":"An Open-Label Extension of the Study XEN496 in Children With KCNQ2 Developmental and Epileptic Encephalopathy","status":"TERMINATED","sponsor":"Xenon Pharmaceuticals Inc.","isPivotal":true,"enrollment":8,"indication":"Epilepsy, Epilepsy in Children","completionDate":"2023-11-17"},{"nctId":"NCT01607346","phase":"Phase 4","title":"An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures","status":"TERMINATED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":10,"indication":"Epilepsy","completionDate":"2016-11-16"},{"nctId":"NCT00612105","phase":"Phase 2","title":"A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated With Pos","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","isPivotal":false,"enrollment":187,"indication":"Postherpetic Neuralgia","completionDate":"2009-12"},{"nctId":"NCT01691872","phase":"Phase 1","title":"An Open-label, Single Centre, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucas","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":0,"indication":"Epilepsy, Partial","completionDate":"2012-10-18"},{"nctId":"NCT01494584","phase":"Phase 2","title":"Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Parti","status":"TERMINATED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":5,"indication":"Epilepsy","completionDate":"2013-04-29"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":null,"mah":null,"brand_name_local":"Trobalt","application_number":"EMEA/H/C/001245"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Trobalt","application_number":null}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}